New Alliance: FCF Life Sciences & Bioscience Valuation

BioScience Valuation

FCF Fox Corporate Finance forms strategic alliance with BioScience Valuation BSV

Munich/Grainau, May 20th, 2020 – The Life Sciences team at Fox Corporate Finance GmbH (“FCF”) is collaborating with BioScience Valuation BSV GmbH (“BSV”) as part of a new strategic alliance that aims to combine the expertise and networks of both companies: FCF promises strong competence in corporate finance and capital markets, while BSV boasts profound expertise in the Health Care and Life Science sectors.

Thanks to the alliance, a more comprehensive range of products and services in the Healthcare/Life Sciences sector will be available to both companies’ clients. The collaboration joins FCF’s expertise in the equity and debt financing of pharmaceutical and biotech enterprises with the scientific and medical know-how BSV brings to the table in complex project, portfolio and company valuations.

Dr. Mathias Schott, Head of FCF Life Sciences, has this to say about the alliance: “We are really looking forward to working with BSV, in our estimation the top consultants for valuations in the Life Sciences market. After over two decades of experience with companies from the pharmaceutical sector, BSV has earned its reputation as a highly competent valuator. They really impressed us with the broad-based scientific and medical expertise that enables BSV to assess the real value of a pharmaceutical project and communicate it in a compelling way. This alliance will enable us to provide our customers with expert, reliable advice in valuation issues, whether they are simply looking to finance a project or pursuing a larger objective.”

Dr. Joachim Greuel, MBA, Managing Director and Co-Founder of BioScience Valuation BSV GmbH, also finds the alliance promising: “To achieve success in the life science sector, companies must be able to understand and communicate the value of their products, and ultimately translate that into funding.

While BSV understands and develops an equity story from the medical and valuation-related perspective, FCF has the capital market expertise to give a story the depth of content it needs to persuade international investors.

We have come to know FCF as one of the leading European investment banks in this sector and look forward to collaborating with them. It is our firm conviction that this combined service portfolio will enable our clients to achieve their corporate and growth strategies on the international stage.”

FCF is a specialized Investment Bank and Financing Specialist, advising public and private small/mid-market companies in the German speaking regions.

FCF focuses on four primary client segments:

  • Mid-Markets: Medium-sized companies with sustainable business models in typical “Mittelstand” industries, such as industrial products and machinery, automotive, communications, logistics, and consumer products
  • Real-Tech: R&D-driven companies in technology sectors, entering the commercialization stage with initial fast-growing revenues
  • Growth: Fast growing companies, that have successfully entered their market, showing double digit revenue numbers and are seeking to expand widely
  • Life Sciences: Highly innovative companies focusing on the development of cuttingedge biotechnology, med-tech, health-tech and pharmaceuticals solutions
FCF arranges, structures, and places equity and debt capital transactions and supports its clients’ growth, IPO/Pre-IPO, acquisition and standard balance sheet (re-)financing strategies at the best available terms.

Founded in 2005 and headquartered in Munich, FCF has direct relationships and works with all leading German, European and international financiers, lenders and investment houses addressing German small/mid-cap companies.

About BSV
Founded in 2000, Bioscience Valuation BSV GmbH is a leading life science valuation company operating on a global scale. The company uses its sharp quantitative analysis skills to help clients in the healthcare sector asses the economic value of their products and communicate the findings in an optimal way. The services provided by Bioscience Valuation form the foundation for a well-informed, highly rational and value-maximizing strategic decision-making process and a persuasive evidence-based valuation of their biotech or pharmaceutical products.


FCF Fox Corporate Finance GmbH
Maximilianstrasse 12-14
80539 Munich
T: +49 (89) 2060 409-0
F: +49 (89) 2060 409-299

BioScience Valuation BSV GmbH
Am Zigeunerbergl 3
82491 Grainau
T: +49 (8821) 9669 79-0
F: +49 (8821) 9779 79–29

Media Contact

newskontor – Agentur für Kommunikation
Marco Cabras, Tel: +49 (0)172 2142968